Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 2,701–2,800 of 15,747
Gregory, G. L., & Copple, I. M. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.12.016 · Cited by 44
The past, present, and future of chemotherapy with a focus on individualization of drug dosing
DeRidder, L. B., Rubinson, D. A., Langer, R., & Traverso, G. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.043 · Cited by 46
Gonçalves, J., Juliano, A. M., Charepe, N. B., Alenquer, M., Athayde, D., Ferreira, F., Archer, M., Amorim, M. J., Serrano, F., & Soares, H. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100468 · Cited by 47
“We looked at humoral response in breastmilk and blood 10 days after first vaccine dose, when protection conferred by mRNA vaccines is starting.(35,36) All lactating women had antispike antibodies in circulation, with 17 of 23 IgAIgGIgM, 2 of 23 IgGIgM, and 1 of 23 IgAIgG (Figure 1A).”
BackgroundThe Cost-Effectiveness of a COVID-19 Vaccine in a Danish Context
Debrabant, K., Kronbak, L. G., & Kronborg, C. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01085-8 · Cited by 45
Haveri, A., Solastie, A., Ekström, N., Österlund, P., Nohynek, H., Nieminen, T. A., PALMU, A. A. I., & Melin, M. M. (2022) · European Journal of Immunology · doi:10.1002/eji.202149785 · Cited by 45
Paredes, M. I., Lunn, S. M., Famulare, M., et al. (2021) · medRxiv · doi:10.1101/2021.09.29.21264272 · Cited by 48
“While studies have shown similar findings for the two mRNA vaccines in regards to efficacy against ancestral lineages (25,26), a study from Qatar showed differences in effectiveness between the two vaccines against infection with the Alpha and Beta lineages (27), potentially impacting the…”
ResultImmunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
Misra, A., & Theel, E. S. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.00482-21 · Cited by 44
Recent Advances in Drug Delivery System Fabricated by Microfluidics for Disease Therapy
Jia, F., Gao, Y., & Wang, H. (2022) · Bioengineering · doi:10.3390/bioengineering9110625 · Cited by 43
COVID-19 vaccination passport: prospects, scientific feasibility, and ethical concerns
Sharun, K., Tiwari, R., Dhama, K., Rabaan, A. A., & Alhumaid, S. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1953350 · Cited by 47
“The two-dose regimen of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine conferred 95% protection against infection in individuals that are 16 years of age or older.(9) Analysis of the real-world dataset confirmed that the inoculation with mRNA COVID-19 vaccine (BNT162b2) substantially reduced the viral load when the v…”
MethodEser, T. M., Baranov, O., Huth, M., Ahmed, M. I. M., Deák, F., Held, K., Lin, L., Pekayvaz, K., Leunig, A., Nicolai, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38020-8 · Cited by 46
The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine
Bartsch, S. M., O’Shea, K. J., Wedlock, P. T., Strych, U., Ferguson, M. C., Bottazzi, M. E., Randall, S. L., Siegmund, S. S., Cox, S. N., Hotez, P. J., et al. (2021) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2021.01.001 · Cited by 38
Perković, M., Gawletta, S., Hempel, T., Brill, S., Nett, E., Şahin, U., & Beißert, T. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.019 · Cited by 48
Self-citationComparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans
Dickerman, B. A., Madenci, A. L., Gerlovin, H., Kurgansky, K. E., Wise, J. K., Muñiz, M. J. F., Ferolito, B. R., GAGNON, D. R., Gaziano, J. M., Cho, K., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.2109 · Cited by 42
An mRNA vaccine to prevent genital herpes
Awasthi, S., & Friedman, H. M. (2021) · Translational research · doi:10.1016/j.trsl.2021.12.006 · Cited by 47
“The mRNA technology had made steady progress in the laboratory and preclinical studies for several decades; however, the true potential of the technology has only been recognized with the impressive success of mRNA COVID-19 vaccines.(44,45) Efforts to develop an effective vaccine for genital herpes have proven difficu…”
Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
Du, L., Yang, Y., Zhang, X., & Li, F. (2022) · Nanoscale · doi:10.1039/d1nr03831a · Cited by 45
Yu, X., Wei, D., Xu, W., Liu, C., Guo, W., Li, X., Tan, W., Liu, L., Zhang, X., Qu, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29477-0 · Cited by 41
SARS-CoV-2 spike E156G/Δ157-158 mutations contribute to increased infectivity and immune escape
Mishra, T. K., Joshi, G., Kumar, A., Dalavi, R., Pandey, P., Shukla, S., Mishra, R. K., & Chande, A. G. (2022) · Life Science Alliance · doi:10.26508/lsa.202201415 · Cited by 45
“Although spike-focused vaccines designed based on the seeding variants have been shown to prevent symptomatic disease effectively (Polack et al, 2020; Voysey et al, 2021), the ability of the emerging variants to breakthrough vaccine-elicited host defense was attributed to escape mutations in the…”
BackgroundPhage Display-Derived Peptide for the Specific Binding of SARS-CoV-2
Yang, F., Liu, L., Neuenschwander, P. F., Idell, S., Vankayalapati, R., Jain, K. G., Du, K., Ji, H., & Yi, G. (2021) · ACS Omega · doi:10.1021/acsomega.1c04873 · Cited by 46
Yeo, K. T., Chia, W. N., Tan, C. W., Ong, C., Yeo, J. G., Zhang, J., Poh, S. L., Lim, A. J. M., Sim, K., Sutamam, N. B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783975 · Cited by 43
“Even so, the initial clinical trials evaluating these novel mRNA vaccines, encoding the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), excluded breastfeeding and lactating women (4, 5).”
BackgroundKasozi, K. I., Laudisoit, A., Osuwat, L. O., Batiha, G. E., omairi, N. E. A., Aigbogun, E., Ninsiima, H. I., Usman, I. M., DeTora, L. M., MacLeod, E. T., et al. (2021) · Vaccines · doi:10.3390/vaccines9030253 · Cited by 39
Evaluation of COVID-19 vaccination strategies with a delayed second dose
Moghadas, S., Vilches, T., Zhang, K., et al. (2021) · medRxiv · doi:10.1101/2021.01.27.21250619 · Cited by 146
Takeuchi, M., Higa, Y., Esaki, A., Nabeshima, Y., & Nakazono, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257668 · Cited by 43
“Local and systemic reactogenicity after the second injection of mRNA vaccines is more common than after the first injection [1, 2, 8].”
BackgroundResultEfros, O., Anteby, R., Halfon, M., Meisel, E., Klang, E., & Soffer, S. (2022) · Vaccines · doi:10.3390/vaccines10010095 · Cited by 42
COVID‐19 and the liver: A 2021 update
Spearman, C. W., Aghemo, A., Valenti, L. V. C., & Sonderup, M. W. (2021) · Liver International · doi:10.1111/liv.14984 · Cited by 43
Loo, J., Sicher, I., Goff, A., Kim, O., Clary, N., Alexeev, A., Sulchek, T., Zamarayeva, A., Han, S., & Calero-Garcia, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-00893-4 · Cited by 43
Liu, Y., Sandmann, F., Barnard, R. C., Pearson, C. A. B., CMMID COVID-19 Working Group, Pastore, R., Pebody, R. G., Flasche, S., & Jit, M. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100267 · Cited by 45
Berild, J. D., Larsen, V. B., Thiesson, E. M., Lehtonen, T., Grøsland, M., Helgeland, J., Wolhlfahrt, J., Hansen, J. V., PALMU, A. A. I., & Hviid, A. P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.17375 · Cited by 42
Yang, J., Luly, K. M., & Green, J. J. (2023) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1853 · Cited by 40
COVID-19: comprehensive review on mutations and current vaccines
Hebbani, A. V., Pulakuntla, S., Pannuru, P., Aramgam, S., Badri, K. R., & Reddy, V. D. (2021) · Archives of Microbiology · doi:10.1007/s00203-021-02606-x · Cited by 44
“Two proline mutations locks the spike protein confirmation in the prefusion conformation (Polack et al. 2020).”
BackgroundNecessity of COVID-19 Vaccination in Persons who have Already had COVID-19
(2021) · doi:10.1101/2021.06.01.21258176 · Cited by 40
“The study follow-up duration was short, being only five months, but this was longer than published mRNA vaccine efficacy studies [1,2], and longer than the follow-up duration of the largest published vaccine effectiveness studies to date [3,4].”
BackgroundResultAdvanced Materials for SARS‐CoV‐2 Vaccines
Mabrouk, M. T., Huang, W., Martínez‐Sobrido, L., & Lovell, J. F. (2022) · Advanced Materials · doi:10.1002/adma.202107781 · Cited by 40
Gringeri, M., Battini, V., Cammarata, G., Mosini, G., Guarnieri, G., Leoni, C., Pozzi, M., Radice, S., Clementi, E., & Carnovale, C. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2044799 · Cited by 41
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
He, X., Su, J., Ma, Y., Zhang, W., & Tang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945930 · Cited by 47
“Among them, seven studies (41, 44, 46, 50, 59, 108, 109) were excluded from the overall analysis because their samples overlapped with another four studies (33, 34, 43, 56).”
ResultMoscara, L., Venerito, V., Martinelli, A., Lorenzo, A. D., Toro, F., Violante, F. S., Tafuri, S., & Stefanizzi, P. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.043 · Cited by 40
Schroeder, D. G., Jang, S., Johnson, D. R., et al. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.25928 · Cited by 40
Cheung, K. S., Mok, C. H., Mao, X., Zhang, R., Hung, I. F., Seto, W., & Yuen, M. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0087 · Cited by 43
Hidaka, D., Ogasawara, R., Sugimura, S., Fujii, F., Kojima, K., Nagai, J., Ebata, K., Okada, K., Kobayashi, N., Ogasawara, M., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03243-2 · Cited by 42
T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVIDPreprint
Visvabharathy, L., Hanson, B. A., Orban, Z. S., Lim, P. H., Palacio, N. M., Jimenez, M., Clark, J. R., Graham, E. L., Liotta, E. M., Tachas, G., et al. (2021) · medRxiv · doi:10.1101/2021.08.08.21261763 · Cited by 43
Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy
Christensen, D., Polacek, C., Sheward, D. J., Hanke, L., Moliner-Morro, A., McInerney, G. M., Murrell, B., Hartmann, K. T., Jensen, H. E., Jungersen, G., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104248 · Cited by 44
Sharma, P., Mishra, S., Basu, S., Tanwar, N., & Kumar, R. (2021) · Cureus · doi:10.7759/cureus.19070 · Cited by 43
“due to a multitude of factors including the dynamics of disease exposure, diminished antibody response in subgroups like the elderly and the immunocompromised, and the emergence of newer mutant strains with greater infectivity and virulence [6,7].”
BackgroundScendoni, R., Petrelli, C., Scaloni, G., & Logullo, F. O. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1954826 · Cited by 38
“In the clinical trials of the vaccine, multiple side effects have been reported ranging from mild symptoms including but not limited to injection site pain, myalgia, fatigue, and fever to more serious side effects including anaphylactic shock.(4,5) A recent article published on February 2021(6) reported the first case…”
BackgroundGlycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine
Wu, C., Cheng, C.-W., Kung, C., Liao, K., Jan, J., Ma, C., & Wong, C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2119995119 · Cited by 41
Vaccination-Associated Myocarditis and Myocardial Injury
Altman, N. L., Berning, A. A., Mann, S., Quaife, R. A., Gill, E. A., Auerbach, S. R., Campbell, T., & Bristow, M. R. (2023) · Circulation Research · doi:10.1161/circresaha.122.321881 · Cited by 49
Safety and Efficacy of the Common Vaccines against COVID-19
Liu, Y., & Ye, Q. (2022) · Vaccines · doi:10.3390/vaccines10040513 · Cited by 50
“Four serious adverse events related to vaccination were reported among BNT162b2 recipients, including shoulder injury, paroxysmal ventricular arrhythmia, right axillary lymphadenopathy, and right leg paresthesia [51].”
BackgroundInfluentialSchmidt, J. J., Borchina, D. N., Klooster, M. V. ́., Soki, K., Okioma, R., Herbst, L., Rodríguez, D., Premužić, V., Büttner, S., Bader, B. D., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab347 · Cited by 43
“Despite the recent advent of SARSCoV-2 vaccines [1, 2], treatment options for those in critical condition are still needed, and yet pharmacologic interventions remain limited.”
Vaccination strategies and transmission of COVID-19: Evidence across advanced countries
Kim, D., & Lee, Y. J. (2022) · Journal of Health Economics · doi:10.1016/j.jhealeco.2022.102589 · Cited by 49
Moghnieh, R., Mekdashi, R., El-Hassan, S., Abdallah, D., Jisr, T., Bader, M., Jizi, I., Sayegh, M. H., & Bizri, A. R. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.007 · Cited by 43
“This can be attributed to the low efficacy achieved by inactivated SARS-CoV-2 virus vaccines, as previously mentioned [4,5,9,11,14].”
BackgroundCOVID‐19 Vaccination and Obesity: Optimism and Challenges
Townsend, M. J., Kyle, T. K., & Stanford, F. C. (2021) · Obesity · doi:10.1002/oby.23131 · Cited by 40
Garg, A. K., Mittal, S., Padmanabhan, P., Desikan, R., & Dixit, N. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.776933 · Cited by 42
Yu, Y., Esposito, D., Kang, Z., Lü, J., Remaley, A. T., Giorgi, V. D., Chen, L. N., West, K. A., & Cao, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-06629-2 · Cited by 42
Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID‐19 vaccine
Tessas, I., & Kluger, N. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17422 · Cited by 40
Bedston, S., Akbari, A., Jarvis, C. I., Lowthian, E., Torabi, F., North, L., Lyons, J., Perry, M., Griffiths, L. J., Owen, R. K., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2021.11.061 · Cited by 46
“The devastation, disruption, and daunting scale of the COVID-19 pandemic has perhaps been matched by the fastest development of vaccines in history [1,2].”
Li, Z., Amaya, L., Ee, A., Wang, S. K., Ranjan, A., Waymouth, R. M., Chang, H. Y., & Wender, P. A. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c02704 · Cited by 41
Hirotsu, Y., & Omata, M. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009619 · Cited by 50
Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2
(2021) · doi:10.1101/2021.03.12.435194 · Cited by 583
Favre, G., Maisonneuve, É., Pomar, L., Winterfeld, U., Daire, C., de Tejada, B. M., Delecraz, D., Campelo, S., Moser, M., Bernasconi, M. T., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100410 · Cited by 44
Dutta, D., Liu, J., & Xiong, H. (2022) · PubMed Central · Cited by 53
Knudson, C. J., Alves-Peixoto, P., Muramatsu, H., Stotesbury, C., Tang, L., Lin, P. J. C., Tam, Y. K., Weissman, D., Pardi, N., & Sigal, L. J. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.011 · Cited by 44
Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low- and Middle-Income Countries
Siedner, M. J., Alba, C., Fitzmaurice, K. P., Gilbert, R. F., Scott, J. A., Shebl, F. M., Ciaranello, A. L., Reddy, K. P., & Freedberg, K. A. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac243 · Cited by 46
Rolfes, L., Härmark, L., Kant, A. C., van Balveren, L., Hilgersom, W. J. A., & van Hunsel, F. P. A. M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.013 · Cited by 42
“Fever was seen in 4% of younger participants after the first dose and in 1% of older participants [6].”
Held, J., Esse, J., Taşçılar, K., Steininger, P. A., Schober, K., Irrgang, P., Alsalameh, R. J., Tenbusch, M., Seggewies, C., & Bogdan, C. (2021) · Vaccines · doi:10.3390/vaccines9101063 · Cited by 40
“In terms of safety, the frequency of mild-to-moderate adverse effects (AEs) of mRNAbased vaccines was substantial [6,12,13].”
BackgroundResultEugenia-Toledo-Romaní, M., Verdecia-Sánchez, L., Rodríguez-González, M., Rodríguez-Noda, L., Valenzuela‐Silva, C., Paredes-Moreno, B., Sánchez-Ramírez, B., Pérez-Nicado, R., González-Mugica, R., Hernández-García, T., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.082 · Cited by 42
Puttarajappa, C. M., Schinstock, C. A., Wu, C. M., Leca, N., Kumar, V., Vasudev, B. S., & Hariharan, S. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.11.017 · Cited by 44
Nanoparticles for Cancer Immunotherapy: Innovations and Challenges
Fallatah, M., Alradwan, I. A., Fayez, N. A., Aodah, A. H., Alkhrayef, M. N., Majrashi, M. A., & Jamous, Y. F. (2025) · Pharmaceuticals · doi:10.3390/ph18081086 · Cited by 57
“LNPs are generally composed of ionizable lipids, phospholipids, cholesterol, PEG-lipids, and the encapsulated nucleic acids [180,181].”
SARS-CoV-2 vaccination in IBD: more pros than cons
D’Amico, F., Rabaud, C., Peyrin‐Biroulet, L., & Danese, S. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00420-w · Cited by 39
County-Level Vaccination Coverage and Rates of COVID-19 Cases and Deaths in the United States
McLaughlin, J. M., Khan, F. L., Pugh, S. J., Swerdlow, D. L., & Jódar, L. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100191 · Cited by 52
TEAD4 as an Oncogene and a Mitochondrial Modulator
Hsu, S., Lin, C., Lin, Y., Collins, C. C., Chen, C., & Kung, H. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.890419 · Cited by 38
(2021) · doi:10.1101/2021.03.24.436620 · Cited by 68
A behavioral economics perspective on the COVID-19 vaccine amid public mistrust
Saleska, J. L., & Choi, K. R. (2021) · Translational Behavioral Medicine · doi:10.1093/tbm/ibaa147 · Cited by 41
Anderson, E. M., Li, S. H., Awofolaju, M., Eilola, T., Goodwin, E. C., Bolton, M. J., Gouma, S., Manzoni, T. B., Hicks, P. D., Goel, R. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111496 · Cited by 37
Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort
Lupica, A., Stefano, V. D., Iacono, S., Pignolo, A., Quartana, M., Gagliardo, A., Fierro, B., & Brighina, F. (2022) · Neurology International · doi:10.3390/neurolint14020033 · Cited by 40
“The most common AEs after BNT162b2 and mRNA-1273 vaccination are local pain (66–83%), followed by asthenia (51–59%), cephalalgia (25–52%), myalgia (19–37%), and gastrointestinal symptoms (8–12%), which are more common after the second dose and in younger subjects [44,45].”
BackgroundResultDavidov, Y., Tsaraf, K., Cohen‐Ezra, O., Likhter, M., Yakov, G. B., Levy, I., Levin, E. G., Lustig, Y., Mor, O., Rahav, G., et al. (2021) · Liver Transplantation · doi:10.1002/lt.26366 · Cited by 41
Taha, Y., Wardle, H., Evans, A. B., Hunter, E., Marr, H. J., Osborne, W., Bashton, M., Smith, D., Burton-Fanning, S., Schmid, M. L., et al. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00491-2 · Cited by 40
Chemotherapy vs. Immunotherapy in combating nCOVID19: An update
Choudhury, A., Mukherjee, G., & Mukherjee, S. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.05.001 · Cited by 44
Bytyci, J., Ying, Y., & Lee, L. Y. W. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1259 · Cited by 46
“11,12 As IC patients mount a weaker immunological response to the vaccine, they are less protected against breakthrough infection, hospitalization, and death in the postvaccination era.”
BackgroundCOVID-19 Vaccines: Current and Future Perspectives
Soraci, L., Lattanzio, F., Soraci, G., Gambuzza, M. E., Pulvirenti, C., Cozza, A., Corsonello, A., Luciani, F., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10040608 · Cited by 43
Šťastná, D., Menkyová, I., Drahota, J., Hrnčiarová, T., Havrdová, E., Vachová, M., Andělová, M., Kleinová, P., Kovářová, I., Krasulová, E., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.104014 · Cited by 40
The Effects of COVID-19 Vaccination on Lactating Women: A Systematic Review of the Literature
Muyldermans, J., Weerdt, L. D., Brabandere, L. D., Maertens, K., & Tommelein, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.852928 · Cited by 46
“Multiple studies showed that sIgA and IgG against the SARSCoV-2 spike protein are present in breast milk after COVID-19 mRNA vaccination (20, 21, 26, 37, 50, 51).”
BackgroundMongin, D., Bürgisser, N., Laurie, G., Schimmel, G., Vu, D., Cullati, S., Covid-SMC Study Group, Mora, L. D. S., Després, L., Dudouit, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41109-9 · Cited by 42
Adverse reactions to Pfizer‐BioNTech vaccination of healthcare workers at Malta's state hospital
Cuschieri, S., Borg, M., Agius, S., Souness, J., Brincat, A., & Grech, V. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14605 · Cited by 40
Kato, H., Miyakawa, K., Ohtake, N., Yamaoka, Y., Yajima, S., Yamazaki, E., Shimada, T., Goto, A., Nakajima, H., & Ryo, A. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.057 · Cited by 41
“Severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine is a powerful tool to control the coronavirus disease-2019 (COVID19) pandemic and the mRNA vaccine BNT162b2 (PfizerBioNTech, USA) is reported to have a vaccine efficacy of 95% [1].”
Protein-based delivery systems for RNA delivery
Zhu, H., Luo, H., Chang, R., Yang, Y., Liu, D., Ji, Y. R., Qin, H., Rong, H., & Yin, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.032 · Cited by 40
Uzakova, A., Yergaliyeva, E. M., Yerlanuly, A., & Mukatayeva, Z. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics18010011 · Cited by 57
“LNPs, leveraging their natural tropism for hepatocytes, have become the basis for siRNA therapies (patisiran) and mRNA vaccines, providing potent therapeutic effects and the potential for rapid global deployment [11,12].”
Maruki, T., Ishikane, M., Suzuki, T., Ujiie, M., Katano, H., & Ohmagari, N. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.055 · Cited by 39
Li, Y.-R., Dunn, Z. S., Garcia, G., Carmona, C., Zhou, Y., Lee, D. P. H., Yu, J., Huang, J., Kim, J. T., Arumugaswami, V., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02787-2 · Cited by 42
“…may stay/recur within human society for an extended period [2], and that vaccines, although highly effective and produced with unprecedented speed [3–5], may not be adequate to end COVID-19 [6] Positive cases in vaccine recipients can occur [7], emergent strains may evade memory responses [8],…”
BackgroundClassification of five SARS-CoV-2 serotypes based on RBD antigenicities
Hu, S., Wu, C., Wu, X., Ma, X., Shu, C., Chen, Q., Zheng, A., Yang, H., Lü, J., Du, P., et al. (2023) · 中国科学通报:英文版 · doi:10.1016/j.scib.2023.09.048 · Cited by 42
Chung, N., Chen, Y.-C., Yang, S.-J., Lin, Y., Dou, H.-Y., Wang, L. H.-C., Liao, C., & Chow, Y. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.024 · Cited by 43
“Other major vaccine design such as mRNA-based vaccines [27,28] also has been shown to elicit a good efficacy in preventing viral transmission.”
Yaamika, H., Muralidas, D., & Elumalai, K. (2023) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2023.08.004 · Cited by 73
“However, underlying medical issues, genetic predisposition, and individual differences in responsiveness to exercise and nutritional changes may all have an impact on the success of these interventions.(61) In some cases, individuals with chronic illnesses or physical limitations may not be able to engage in vigorous…”
BackgroundGilboa, M., Mandelboim, M., Indenbaum, V., Lustig, Y., Cohen, C., Rahav, G., Asraf, K., Amit, S., Jaber, H., Nemet, I., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab584 · Cited by 42
Touizer, E., Alrubayyi, A., Rees-Spear, C., Fisher-Pearson, N., Griffith, S. A., Muir, L., Pellegrino, P., Waters, L. J., Burns, F. M., Loes, S. K., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00099-0 · Cited by 38
Chirumbolo, S. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26922 · Cited by 41
Stein, M., Ashkenazi‐Hoffnung, L., Greenberg, D., Dalal, I., Livni, G., Chapnick, G., Stein‐Zamir, C., Ashkenazi, S., Sagie, L. H., & Grossman, Z. (2022) · Vaccines · doi:10.3390/vaccines10010081 · Cited by 44
“The original clinical study involving 40,000 individuals showed high safety of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine [78]; the rate of significant adverse events occurring soon after vaccine administration was minimal.”
BackgroundMethodDu, Y., Chen, L., & Shi, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.829176 · Cited by 46
“In addition to six included RCTs, a comprehensive search identified three relevant trials (20, 39, 40) that included adolescents, all of which confirmed good safety and immunogenicity of the vaccine in this age group but were not included in the review because no information was specifically provided for specific age…”
BackgroundDooling, K. L., Gargano, J. W., Moulia, D., Wallace, M. M., Rosenblum, H. G., Blain, A. E., Hadler, S. C., Plumb, I. D., Moline, H. L., Gerstein, J., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7038e2 · Cited by 43
SARS-CoV-2 vaccines in patients with SLE
Tang, W., Askanase, A., Khalili, L., & Merrill, J. T. (2021) · Lupus Science & Medicine · doi:10.1136/lupus-2021-000479 · Cited by 39
Are inhaled mRNA vaccines safe and effective? A review of preclinical studies
Jansen, E. M., Frijlink, H. W., Hinrichs, W. L. J., & Ruigrok, M. J. R. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2131767 · Cited by 37
“BNT162b2 and mRNA-1273, for example, produce full-length spike proteins of SARS-CoV-2 and BNT162b1 encodes for the SARS-CoV-2 receptor-binding domain (RBD) [1,2,77].”
BackgroundThe rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
Soh, S. M., Kim, Y., Kim, C., Jang, U. S., & Lee, H.-R. (2021) · The Journal of Microbiology · doi:10.1007/s12275-021-1348-5 · Cited by 53
Appaneal, H. J., Lopes, V., Puzniak, L., Zasowski, E. J., Jódar, L., McLaughlin, J. M., & Caffrey, A. R. (2025) · Nature Communications · doi:10.1038/s41467-025-59344-7 · Cited by 40
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.